My Take: Essential Scientific Advances in Epilepsy Treatment
  • CME

April 17 – 22, 2021; Virtual Meeting
My review of new evidence on the safety and efficacy of antiseizure medications presented at the AAN Annual Meeting 2021.
Anli A. Liu, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: May 28, 2021 Expiration: May 27, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Critically evaluate study results from recent trials of epilepsy regarding treatment efficacy and safety
  • Describe how new trial data will affect/change the management of patients with epilepsy


Provided by Clinical Care Options

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Greenwich Biosciences, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Anli A. Liu, MD

Associate Professor of Medicine
Division of Epilepsy
Department of Neurology
NYU Langone
New York, New York

Anli A. Liu, MD, has no relevant conflicts of interest to report.


Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for a multidisciplinary audience of neurologists, pediatric neurologists, pediatricians, internists and hospitalists, emergency physicians, advanced practitioners, and other healthcare professionals involved in the diagnosis and management of patients with epilepsy.


The goal of this activity is to update healthcare professionals with the most current clinical and scientific advances in epilepsy to be presented at AAN 2021.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 28, 2021, through May 27, 2022:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From Clinical Care Options (CCO), new data from AAN 2021 on cenobamate, lamotrigine, carbamazepine for uncontrolled focal seizures from the C021 study

Released: April 26, 2021

From Clinical Care Options (CCO), new data from AAN 2021 on CBD add-on therapy in treatment-resistant epilepsy

Released: April 26, 2021

Expert commentary from CCO on key clinical information about each FDA-approved agent for treating spinal muscular atrophy (SMA)

Nancy L. Kuntz, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Nurse Practitioners: 0.25 NAPNAP CE contact hours Released: October 23, 2020 Expired: No longer available for credit

Expert commentary on how to support, counsel, and educate families with a new diagnosis of spinal muscular atrophy (SMA), from Clinical Care Options (CCO)

Vanessa Battista, MS, RN, CPNP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Nurse Practitioners: 0.25 NAPNAP CE contact hours Released: October 5, 2020 Expired: No longer available for credit

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings